Mallinckrodt PLC MNK, -5.06% shares dropped 8% in heavy morning trade Monday after short-seller Citron Research released a new report criticizing the pharmaceutical company. Citron Research has previously targeted the drugmaker, comparing it to Valeant VRX, -1.36% in a tweet in 2015. In the Monday report, the short-seller focused on Mallinckrodt's H.P. Acthar Gel, which can be used for a variety of diseases including multiple sclerosis, dermatological diseases and respiratory diseases. Massive price increases over the years have brought Acthar's price to nearly $40,000 a vial, and the product brings in more than $1 billion in revenue for Mallinckrodt.
http://www.marketwatch.com/story/mallinckrodt-stock-drops-8-on-new-citron-research-report-2017-06-05
---------------------------------
Wonder whether MSB have the right partnership, perhaps making stem cell treatment beyond the reach of most people in future.
MNK cashing up again?, page-22
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
-0.008(0.54%) |
Mkt cap ! $1.581B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.42 | $1.38 | $3.338M | 2.396M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 26201 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 44644 | 36 |
View Market Depth
| Last trade - 15.21pm 10/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |